Anti-Mouse IL-12 p40 Antibody (C17.8) is a rat-derived anti-mouse IL-12 p40 IgG2a κ type antibody inhibitor. Anti-Mouse IL-12 p40 Antibody (C17.8) binds p40 subunit of IL-12. Anti-Mouse IL-12 p40 Antibody (C17.8) can be used for the researches of inflammation, immunology and metabolic disease, such as diabetes and arthritis [1] [2] [3].
In Vivo, Anti-Mouse IL-12 p40 Antibody (C17.8) (500 μg, i.p., twice a week during 5-30 weeks) exhibits suppression of both insulitis and diabetes in non-obese diabetic mice models[1]. Anti-Mouse IL-12 p40 Antibody (C17.8) (200 μg, i.p., for 6 consecutive days) results in the enhancement of diabetes in 2-week-old non-obese diabetic mice models[1]. Anti-Mouse IL-12 p40 Antibody (C17.8) (0.5 mg, i.p., 2 h before injection of SCW fragments) suppresses murine streptococcal cell wall (SCW)-induced arthritis[2]. Anti-Mouse IL-12 p40 Antibody (C17.8) (0.5 mg, i.p., once a week) prolongs survival in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis mice models[3].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Fujihira K, et al. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes. 2000 Dec;49(12):1998-2006.
[2]. Joosten LA, et al. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra. Ann Rheum Dis. 2000 Mar;59(3):196-205.
[3]. Gaignage M, et al. Novel antibodies that selectively block mouse IL-12 enable the re-evaluation of the role of IL-12 in immune protection and pathology. Eur J Immunol. 2021 Jun;51(6):1482-1493.
In Vivo, Anti-Mouse IL-12 p40 Antibody (C17.8) (500 μg, i.p., twice a week during 5-30 weeks) exhibits suppression of both insulitis and diabetes in non-obese diabetic mice models[1]. Anti-Mouse IL-12 p40 Antibody (C17.8) (200 μg, i.p., for 6 consecutive days) results in the enhancement of diabetes in 2-week-old non-obese diabetic mice models[1]. Anti-Mouse IL-12 p40 Antibody (C17.8) (0.5 mg, i.p., 2 h before injection of SCW fragments) suppresses murine streptococcal cell wall (SCW)-induced arthritis[2]. Anti-Mouse IL-12 p40 Antibody (C17.8) (0.5 mg, i.p., once a week) prolongs survival in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis mice models[3].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Fujihira K, et al. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes. 2000 Dec;49(12):1998-2006.
[2]. Joosten LA, et al. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra. Ann Rheum Dis. 2000 Mar;59(3):196-205.
[3]. Gaignage M, et al. Novel antibodies that selectively block mouse IL-12 enable the re-evaluation of the role of IL-12 in immune protection and pathology. Eur J Immunol. 2021 Jun;51(6):1482-1493.